Get the Stockscreener App
11.52
4.54%
0.50
Arvinas Inc stock is traded at $11.52, with a volume of 1.81M.
It is up +4.54% in the last 24 hours and up +19.25% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$11.02
Open:
$11
24h Volume:
1.81M
Relative Volume:
0.76
Market Cap:
$739.86M
Revenue:
$161.10M
Net Income/Loss:
$-308.60M
P/E Ratio:
-2.4668
EPS:
-4.67
Net Cash Flow:
$-259.90M
1W Performance:
+8.99%
1M Performance:
+19.25%
6M Performance:
+84.32%
1Y Performance:
-54.12%
1-Day Range:
$10.98
$11.73
1-Week Range:
$10.42
$14.22
52-Week Range:
$5.90
$27.00
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
11.52 | 707.75M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Downgrade | Goldman | Neutral → Sell |
| Sep-24-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Promising Biotech Stocks To ConsiderNovember 18th - MarketBeat
Can Arvinas Inc. stock beat market expectations this quarterTrend Reversal & Fast Exit/Entry Strategy Plans - newser.com
Arvinas (NASDAQ:ARVN) Stock Price Down 7%Should You Sell? - MarketBeat
Why Arvinas Inc. stock attracts high net worth investorsRate Cut & High Win Rate Trade Tips - newser.com
Is Arvinas Inc. stock attractive after correctionJuly 2025 Technicals & Long-Term Safe Investment Ideas - newser.com
Connor Clark & Lunn Investment Management Ltd. Takes Position in Arvinas, Inc. $ARVN - MarketBeat
Arvinas Inc. stock chart pattern explainedSell Signal & Technical Pattern Recognition Alerts - newser.com
Is Arvinas Inc. still worth holding after the dipFed Meeting & Target Return Focused Stock Picks - newser.com
Arvinas Inc. (ARVN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Arvinas Inc. stock a top pick in earnings seasonJuly 2025 Earnings & Long-Term Safe Return Strategies - newser.com
Reversal indicators forming on Arvinas Inc. stockWeekly Stock Summary & AI Forecast Swing Trade Picks - newser.com
How Arvinas Inc. stock benefits from strong dollarForecast Cut & Real-Time Market Trend Scan - newser.com
Can Arvinas Inc. stock beat analyst upgradesQuarterly Performance Summary & Expert Curated Trade Ideas - newser.com
Arvinas (NASDAQ:ARVN) Shares Gap UpShould You Buy? - MarketBeat
Can technical indicators confirm Arvinas Inc.’s reversalJuly 2025 Macro Moves & Free Daily Entry Point Trade Alerts - newser.com
Arvinas, Inc.Common Stock (NQ: ARVN - FinancialContent
Arvinas’ Stock Surge: Analyzing the Movement - StocksToTrade
Revisiting the Narrative for Arvinas as Analyst Views Shift with New Pipeline and Partner Risks - Yahoo Finance
Is Arvinas Inc. stock affected by interest rate hikesSell Signal & Reliable Price Action Trade Plans - newser.com
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Will Arvinas Inc. stock outperform tech sector in 2025Trade Signal Summary & Safe Entry Momentum Stock Tips - newser.com
Has Arvinas Inc. formed a bullish divergence2025 Growth vs Value & Daily Stock Trend Reports - newser.com
Arvinas (NASDAQ:ARVN) Trading 8% HigherHere's Why - MarketBeat
Historical volatility pattern of Arvinas Inc. visualizedWeekly Stock Summary & Proven Capital Preservation Methods - newser.com
How to escape a deep drawdown in Arvinas Inc.Weekly Trade Recap & Daily Risk Controlled Trade Plans - newser.com
Published on: 2025-11-15 14:53:07 - newser.com
Quinn Opportunity Partners LLC Invests $524,000 in Arvinas, Inc. $ARVN - MarketBeat
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):